Independent Medical Education
Request for Proposals (RFP)

PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate Cancer (mPC) Landscape

Competitive Grant Program – Pfizer Internal Review Process

Date RFP Issued: June 26, 2025

I. Eligibility

Geographic Scope/Location of Project:

United States

Applicant Eligibility Criteria

- **Applicant organizations to this RFP must be based in the United States.**
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- For projects offering continuing education credit in the United States, the requesting organization must be accredited.

II. Requirements

General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on increasing healthcare professional knowledge and competence in the following areas:

- Guideline concordance and best practices for integration of testing into clinical practice, including: when to order testing and how to interpret results of biomarkers and genetic mutations (inclusive of all HRR mutations, i.e. BRCA and non-BRCA), the role of the multidisciplinary team in ordering tests, and education on strategies to identify and remove barriers to appropriate testing for patients with prostate cancer.
- Emerging data on efficacy and safety regarding PARPi's used in the treatment of mPC including better understanding of: 1) the mechanism of action and the biological and clinical rationale for PARPi combinations and; 2) clinical safety, treatment sequencing and patient subgroup data
- Clinical data regarding PARPi combinations and how to mitigate associated side effects for optimal patient care, including but not limited to, the role of the multidisciplinary team in ongoing therapy management.
- Best practices for initiating guideline concordant care for patients with mPC in community healthcare settings for optimal therapy management of PARPi combinations in prostate cancer including but not limited to, implementation of genetic testing workflows and encouraging patient engagement in treatment decisions and clinical trial participation.

Examples of educational formats that will be considered under this RFP include but are not limited to:

- On-agenda educational sessions during live conferences
- Multi-company supported, stand-alone symposia
- Expert interviews recorded at live conferences, conference coverage reviews
- Online articles, newsletter articles, training courses, webinars
- Social media posted & linked content
- Videos, podcasts, infographics, animations

It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.

Target Audience:

Community oncologists, urologists, oncology nurses and nurse practitioners, physician assistants, pharmacists, genetic counselors, and other healthcare professionals involved in the care and treatment of patients with mCRPC.

Expected Approximate Monetary Range of Grant Applications:

Individual projects requesting ***up to*** $350,000 will be considered. The estimated total available budget related to this RFP is $850,000. Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs. Multi-supported educational programs encouraged.

Key Dates:

- RFP release date: June 26, 2025
- Grant Application due date: August 21, 2025

  Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: Week of September 15, 2025
- Grants will be distributed following a fully executed agreement.
- Anticipated Approximate Project Start and End Dates: October 2025 to April 2027 (18 months preferred maximum length; projects may be shorter than 18 months)

How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create your password”. *[Note: there are individual portals for each grant application type. Please be sure to use the URL above.]*
- Click the “Start A New Knowledge Gap Application" button.
- In the application:
  - For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)
  - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes
  - Select the following Competitive Grant Program Name: **2025 ONC US PARPi mCRPC IME**
  - Select the following Primary Area of Interest: Oncology – Genitourinary - KG
- Requirements for submission:

  Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

IMPORTANT: Be advised applications submitted after the due date will not be reviewed.

Questions:

If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Lori Carpenter (lori.carpenter@pfizer.com), with the subject line "2025 ONC US PARPi mCRPC IME"

Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement.
- Under Pfizer's competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

Review and Approval Process:

Grant requests received in response to a general RFP are reviewed by Pfizer colleagues to make final grant decisions.

Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

About Pfizer External Research & Grants

Pfizer External Research & Grants (ER&G) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's ER&G competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Appendix

General RFP Submission Requirements

Applications will be accepted via the online portal listed in the How to Submit section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

Needs Assessment for the Project

- Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

Project Design and Methods

- Describe the planned project, the educational approach, and the way the planned methods address the established need.
- Describe any plans as to how the content will be assessed to ensure it is up to date over the education implementation and delivery lifecycle.

Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget please keep the following items in mind:
  - Independent Medical Education Grants awarded by ER&G cannot be used to purchase therapeutic assets (prescription or non-prescription).
  - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please click here for details. General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.